Page 17 - Priority Review News Today

Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial...

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024.

Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.

The Food and Drug Administration granted a priority review to Blincyto for the treatment of early-stage CD19-positive B-cell acute lymphoblastic leukemia.

A new proof-of-concept observation study reports the dual GLP-1/GIP agonist's positive efficacy and safety for adults with T1D.

Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population Adults aged 50 and above with underlying medical...

PHILADELPHIA--(BUSINESS WIRE)-- #AREXVY--GSK’s RSV vaccine, AREXVY, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk ...

The FDA has granted Priority Review to oral ALK inhibitor Alecensa (alectinib) for patients with early-stage ALK-positive non-small cell lung cancer.

The FDA has granted Priority Review to Arexvy for the prevention of RSV disease in adults aged 50 to 59 years who are at increased risk for RSV disease.

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer